Poly(Alkyl Cyanoacrylate) nanoparticles for drug delivery and vaccine development

Colloids in Drug Delivery

Volumn , Issue , 2016, Pages 99-136

  Graf, Anja ^a   Krauel Göllner, Karen ^b   Rades, Thomas ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOACRYLATES; VACCINE DEVELOPMENT;

DRUG DELIVERY;

EID: 84920539125     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Aboubakar, M., P. Couvreur, H. Pinto-Alphandary, B. Gouritin, B. Lacour, R. Farinotti, F. Puisieux, and C. Vauthier, 2000. Insulin-loaded nanocapsules for oral administration: In vitro and in vivo investigation. Drug Development Research 49(2): 109-117.
2. Aboubakar, M., F. Puisieux, P. Couvreur, M. Deyme, and C. Vauthier, 1999a. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. Journal of Biomedical Materials Research 47(4): 568-576.
3. Aboubakar, M., F. Puisieux, P. Couvreur, and C. Vauthier, 1999b. Physico-chemical characterization of insulinloaded poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. International Journal of Pharmaceutics 183(1): 63-66.
4. Agarwal, A., A. Varma, and C. Sarkar, 1998. Histopathological changes following the use of biological and synthetic glue for dural grafts. An experimental study. British Journal of Neurosurgery 12: 213-216.
5. Alany, R. G., G. M. M. El Maghraby, K. Krauel-Goellner, and A. Graf, 2008. Microemulsion systems and their potential as drug carriers. In Structure, Interactions and Dynamic Processes in Microemulsions. M. Fanun (Ed.). Taylor&Francis/CRC Press: Boca Raton, Florida.
6. Al Khouri Fallouh, N., L. Roblot-Treupel, H. Fessi, J. P. Devissaguet, and F. Puisieux, 1986. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. International Journal of Pharmaceutics 28(2-3): 125-132.
7. Alyautdin, R. N., V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter, 1997. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharmaceutical Research 14: 325-328.
8. Alyautdin, R. N., E. B. Tezikov, P. Ramge, D. A. Kharkevich, D. J. Begley, and J. Kreuter, 1998. Significant entry of tubocurarine into the brain of rats with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles:An in situ brain perfusion study. Journal of Microencapsulation 15(1): 67-74.
9. Ammoury, N., H. Fessi, J. P. Devissaguet, M. Dubrasquet, and S. Benita, 1991. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly- (isobutyl-cyanoacrylate) nanocapsules in rats. Pharmaceutical Research 8(1): 101-105.
10. Aprahamian, M., C. Michel, W. Humbert, J. P. Devissaguet, and C. Damge, 1987. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biology of the Cell 61(1-2): 69-76.
11. Arias, J. L., V. Gallardo, S. A. Gomez-Lopera, R. C. Plaza, and A. V. Delgado, 2001. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. Journal of Controlled Release 77(3): 309-321.
12. Arias, J. L., V. Gallardo, M. A. Ruiz, and A. V. Delgado, 2007. Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. International Journal of Pharmaceutics 337(1-2): 282-290.
13. Balnois, E., G. Papastavrou, and K. J. Wilkinson, 2007. Force microscopy and force measurements of environmental colloids. In Environmental Colloids and Particles: Behaviour, Structure and Characterization, K. J. Wlkinson and J. R. Lead (Eds). Chichester, U.K.: Wiley.
14. Barr, I. G. and G. F. Mitchell, 1996. ISCOMs (immunostimulating complexes): The first decade. Immunology and Cell Biology 74(1): 8-25.
15. Beck, P. H., J. Kreuter, W. E. G. Muller, and W. Schatton, 1994. Improved peroral delivery of avarol with polybutylcyanoacrylate nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 40(3):134-137.
16. Behan, N. and C. Birkinshaw, 2001. Preparation of poly(butyl cyanoacrylate) nanoparticles by aqueous dispersion polymerisation in the presence of insulin. Macromolecular Rapid Communications 22(1): 41-43.
17. Behan, N., C. Birkinshaw, and N. Clarke, 2001. Poly n-butyl cyanoacrylate nanoparticles: A mechanistic study of polymerisation and particle formation. Biomaterials 22(11): 1335-1344.
18. Bogdan, M., A. Nan, C. V. L. Pop, L. Barbu-Tudoran, and I. Ardelean, 2008. Preparation and NMR characterization of polyethyl-2-cyanoacrylate nanocapsules. Applied Magnetic Resonance 34(1): 111-119.
19. Bootz, A., T. Russ, F. Gores, M. Karas, and J. Kreuter, 2005. Molecular weights of poly(butyl cyanoacrylate) nanoparticles determined by mass spectrometry and size exclusion chromatography. European Journal of Pharmaceutics and Biopharmaceutics 60(3): 391-399.
20. Bootz, A., V. Vogel, D. Schubert, and J. Kreuter, 2004. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butylcyanoacrylate) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 57(3): 369-375.
21. Boudad, H., P. Legrand, G. Lebas, M. Cheron, D. Duchene, and G. Ponchel, 2001. Combined hydroxypropyl-[beta]-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. International Journal of Pharmaceutics 218(1-2): 113-124.
22. Brayden, D. J., 2001. Oral vaccination in man using antigens in particles: Current status. European Journal of Pharmaceutical Sciences 14(3): 183-189.
23. Brigger, I., J. Morizet, L. Laudani, G. Aubert, M. Appel, V. Velasco, M.-J. Terrier-Lacombe, D. Desmaele, et al., 2004. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. Journal of Controlled Release 100(1): 29-40.
24. Bu, H.-Z., H. J. Gukasyan, L. Goulet, X.-J. Lou, C. Xiang, and T. Koudriakova, 2007. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Current Drug Metabolism 8(2): 91-107.
25. Calvo, P., B. Gouritin, H. Chacun, D. Desmaele, J. D'Angelo, J. P. Noel, D. Georgin, et al., 2001. Longcirculating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceutical Research 18(8): 1157-1166.
26. Chauvierre, C., D. Labarre, P. Couvreur, and C. Vauthier, 2003. Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharmaceutical Research 20(11): 1786-1793.
27. Chiannilkulchai, N., N. Ammoury, J. Caillou, J. Ph. Devissaguet, and P. Couvreur, 1990. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemotherapy and Pharmacology 26(2): 122-126.
28. Chouinard, F., S. Buczkowaski, and V. Lenaerts, 1994. Poly(alkylcyanoacrylate) nanocapsules: Physicochemical characterization and mechanism of formation. Pharmaceutical Research 11(6): 869-874.
29. Chouinard, F., F. W. K. Kan, J.-C. Leroux, C. Foucher, and V. Lenaerts, 1991. Preparation and purification of polyisohexylcyanoacrylate nanocapsules. International Journal of Pharmaceutics 72(2): 211-217.
30. Cournarie, F., D. Auchere, D. Chevenne, B. Lacour, M. Seiller, and C. Vauthier, 2002. Absorption and effi- ciency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats. International Journal of Pharmaceutics 242(1-2): 325-328.
31. Cournarie, F., M. Cheron, M. Besnard, and C. Vauthier, 2004. Evidence for restrictive parameters in formulation of insulin-loaded nanocapsules. European Journal of Pharmaceutics and Biopharmaceutics 57(2):171-179.
32. Couvreur, P., 1988. Polyalkylcyanoacrylates as colloidal drug carriers. Critical Reviews in Therapeutic Drug Carrier Systems 5(1): 1-20.
33. Couvreur, P., G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, 2002. Nanocapsule technology: A review. Critical Reviews in Therapeutic Drug Carrier Systems 19(2): 99-134.
34. Couvreur, P., G. Couarraze, J. Devissaguet, and F. Puisieux, 1996. Nanoparticles: Preparation and characterisation. In Microencapsulation: Methods and Industrial Applications, S. Benita (Ed.). New York: Marcel Dekker.
35. Couvreur, P., C. Dubernet, and F. Puisieux, 1995. Controlled drug delivery with nanoparticles: Current possibilities and future trends. European Journal of Pharmaceutics and Biopharmaceutics 41(1): 2-13.
36. Couvreur, P., B. Kante, M. Roland, P. Guiot, P. Bauduin, and P. Speiser, 1979. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers-Preparation, morphological and sorptive properties. Journal of Pharmacy and Pharmacology 31(5): 331-332.
37. Couvreur, P., V. Lenaerts, B. Kante, M. Roland, and P. Speiser, 1980. Oral and parenteral administration of insulin associated to hydrolysable nanoparticles. Acta Pharmaceutica Technologica 26: 220-222.
38. Couvreur, P. and C. Vauthier, 2006. Nanotechnology: Intelligent design to treat complex disease. Pharmaceutical Research 23(7): 1417-1450.
39. Damge, C., M. Aprahamian, G. Balboni, A. Hoeltzel, V. Andrieu, and J. P. Devissaguet, 1987. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. International Journal of Pharmaceutics 36(2-3): 121-125.
40. Damge, C., D. Hillaire-Buys, R. Puech, A. Hoeltzel, C. Michel, and G. Ribes, 1995. Effects of orally administered insulin nanocapsules in normal and diabetic dogs. Diabetes, Nutrition and Metabolism-Clinical and Experimental 8(1): 3-9.
41. Damge, C., P. Maincent, and N. Ubrich, 2007. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. Journal of Controlled Release 117(2): 163-170.
42. Damge, C., C. Michel, M. Aprahamian, and P. Couvreur, 1988. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37(2): 246-251.
43. Damge, C., C. Michel, M. Aprahamian, P. Couvreur, and J. P. Devissaguet, 1990. Nanocapsules as carriers for oral peptide delivery. Journal of Controlled Release 13(2-3): 233-239.
44. Damge, C., J. Vonderscher, P. Marbach, and M. Pinget, 1997a. Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. Journal of Pharmacy and Pharmacology 49(10): 949-954.
45. Damge, C., H. Vranckx, P. Balschmidt, and P. Couvreur, 1997b. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. Journal of Pharmaceutical Sciences 86(12): 1403-1409.
46. Das, D. and S. Lin, 2005. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. Journal of Pharmaceutical Sciences 94(6): 1343-1353.
47. de Kozak, Y., K. Andrieux, H. Villarroya, C. Klein, B. Thillaye-Goldenberg, M.-C. Naud, E. Garcia, and P. Couvreur, 2004. Intraocular injection of tamoxifen-loaded nanoparticles: A new treatment of experimental autoimmune uveoretinitis. European Journal of Immunology 34(12): 3702-3712.
48. Demana, P. H., C. Fehske, K. White, T. Rades, and S. Hook, 2004. Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunology and Cell Biology 82(5): 547-554.
49. Desai, S. D. and J. Blanchard, 2000. PluronicR F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Delivery 7(4): 201-207.
50. Duchene, D., G. Ponchel, and D. Wouessidjewe, 1999. Cyclodextrins in targeting: Application to nanoparticles. Advanced Drug Delivery Reviews 36(1): 29-40.
51. Ellens, H., E. Mayhew, and Y. M. Rustum, 1982. Reversible depression of the reticuloendothelial system by liposomes. Biochimica Biophysica Acta 714: 479-485.
52. El-Samaligy, M. S., P. Rohdewald, and H. A. Mahmoud, 1986. Polyalkyl cyanoacrylate nanocapsules. Journal of Pharmacy and Pharmacology 38(3): 216-218.
53. El-Samaligy, M. S., Y. Rojanasakul, J. F. Charlton, G. W. Weinstein, and J. K. Lim, 1996. Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit's eye. Drug Delivery:Journal of Delivery and Targeting of Therapeutic Agents 3(2): 93-97.
54. Fernandez-Urrusuno, R., E. Fattal, D. Porquet, J. Feger, and P. Couvreur, 1995. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicology and Applied Pharmacology 130(2): 272-279.
55. Fernandez-Urrusuno, R., E. Fattal, J. M. Rodrigues, J. Feger, P. Bedossa, and P. Couvreur, 1996. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. Journal of Biomedical Materials Research 31: 401-408.
56. Fitch, R. M. and C.-H. Tsai, 1970. Polymer colloids: Particle formation in nonmicellar systems. Journal of Polymer Science Part B: Polymer Letters 8(10): 703-710.
57. Fresta, M., G. Cavallaro, G. Giammona, E. Wehrli, and G. Puglisi, 1996. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 17(8): 751-758.
58. Fresta, M., G. Fontana, C. Bucolo, G. Cavallaro, G. Giammona, and G. Puglisi, 2001. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphereencapsulated acyclovir. Journal of Pharmaceutical Sciences 90(3): 288-297.
59. Friese, A., E. Seiller, G. Quack, B. Lorenz, and J. Kreuter, 2000. Increase of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. European Journal of Pharmaceutics and Biopharmaceutics 49(2): 103-109.
60. Gallardo, M., G. Couarraze, B. Denizot, L. Treupel, P. Couvreur, and F. Puisieux, 1993. Study of the mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate. International Journal of Pharmaceutics 100(1-3): 55-64.
61. Gasco, M. R. and M. Trotta, 1986. Nanoparticles from microemulsions. International Journal of Pharmaceutics 29(2-3): 267-268.
62. Gelperina, S. E., A. S. Khalansky, I. N. Skidan, Z. S. Smirnova, A. I. Bobruskin, S. E. Severin, B. Turowski, et al., 2002. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicology Letters 126(2): 131-141.
63. Gibaud, S., C. Rousseau, C. Weingarten, R. Favier, L. Douay, J. P. Andreux, and P. Couvreur, 1998. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). Journal of Controlled Release 52(1-2): 131-139.
64. Graf, A., E. Ablinger, S. Peters, A. Zimmer, S. Hook, and T. Rades, 2008a. Microemulsions containing lecithin and sugar-based surfactants: Nanoparticle templates for delivery of proteins and peptides. International Journal of Pharmaceutics 350(1-2): 351-360.
65. Graf, A., K. S. Jack, A. K. Whittaker, S. M. Hook, and T. Rades, 2008b. Protein delivery using nanoparticles based on microemulsions with different structure-types. European Journal of Pharmaceutical Sciences 33(4-5): 434-444.
66. Graf, A., T. Rades, and S. M. Hook, 2009. Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: Optimisation and in vivo evaluation. European Journal of Pharmaceutical Sciences 37(1): 53-61.
67. Grangier, J. L., M. Puygrenier, J. C. Gautier, and P. Couvreur, 1991. Nanoparticles as carriers for growth hormone releasing factor. Journal of Controlled Release 15(1): 3-13.
68. Gulyaev, A. E., S. E. Gelperina, A. S. Skidan, A. S. Antropov, G. Y. Kivman, and J. Kreuter, 1999. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research 16: 1564-1569.
69. Hillaireau, H., T. Le Doan, H. Chacun, J. Janin, and P. Couvreur, 2007. Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. International Journal of Pharmaceutics 331(2): 148-152.
70. Hillery, A. M., I. Toth, and A. T. Florence. 1996a. Biological activity of luteinizing hormone releasing hormone after oral dosing with a nanoparticulate delivery system: Co-polymerised peptide particles. Pharmaceutical Science 2:281-283.
71. Hillery, A. M., I. Toth, and A. T. Florence. 1996b. Co-polymerised peptide particles II: Oral uptake of a novel copolymeric nanoparticulate delivery system for peptides. Journal of Controlled Release 42(1): 65-73.
72. Hoffmann, D. and C. Mayer, 2000. Cross polarization induced by temporary adsorption: NMR investigations on nanocapsule dispersions. Journal of Chemical Physics 112(9): 4242-4250.
73. Holtzscherer, C., J. P. Durand, and F. Candau, 1987. Polymerization of acrylamide in nonionic microemulsions-Characterization of the microlattices and polymers formed. Colloid and Polymer Science 265(12): 1067-1074.
74. Hubert, B., J. Atkinson, M. Guerret, M. Hoffman, J. P. Devissaguet, and P. Maincent, 1991. The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharmaceutical Research 8(6): 734-738.
75. Jani, P., G. W. Halbert, J. Langridge, and A. T. Florence, 1990. Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. Journal of Pharmacy and Pharmacology 42:821-826.
76. Kante, B., P. Couvreur, G. Dubois-Krack, C. De Meester, P. Guiot, M. Roland, M. Mercier, and P. Speiser, 1982. Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles. Journal of Pharmceutical Sciences 71(7): 786-790.
77. Kawamura, S., H. Hadeishi, A. Suzuki, and N. Yasui, 1998. Arterial occlusive lesions following wrapping and coating and unruptured aneurysms. Neurologia Medico-Chirurfica 38(1): 12-18.
78. Krauel, K., 2005. Formulation and characterisation of nanoparticles based on biocompatible microemulsions. PhD dissertaion, University of Otago, Dunedin, School of Pharmacy.
79. Krauel, K., N. M. Davies, S. Hook, and T. Rades, 2005. Using different structure types of microemulsions for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization. Journal of Controlled Release 106(1-2): 76-87.
80. Krauel, K., L. Girvan, S. Hook, and T. Rades, 2007. Characterisation of colloidal drug delivery systems from the naked eye to cryo-FESEM. Micron 38(8): 796-803.
81. Krauel, K., A. Graf, S. M. Hook, N. M. Davies, and T. Rades, 2006. Preparation of poly (alkylcyanoacrylate) nanoparticles by polymerization of water-free microemulsions. Journal of Microencapsulation 23(5): 499-512.
82. Krauel, K., T. Pitaksuteepong, N. M. Davies, and T. Rades, 2004. Entrapment of bioactive molecules in poly (alkylcyanoacrylate) nanoparticles. American Journal of Drug Delivery 2(4): 251-259.
83. Kreuter, J., 1988. Possibilities of using nanoparticles as carriers for drugs and vaccines. Journal of Microencapsulation 5(2): 115-127.
84. Kreuter, J. (Ed.), 1994. Nanoparticles. In Colloidal Drug Delivery Systems. New York: Marcel Dekker.
85. Kreuter, J., R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov, 1995. Passage of peptides through the blood- brain barrier with colloidal polymer particles (nanoparticles). Brain Research 674: 171-174.
86. Lambert, G., E. Fattal, H. Pinto-Alphandary, A. Gulik, and P. Couvreur, 2000b. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharmaceutical Research 17(6): 707-714.
87. Lambert, G., J. R. Bertrand, E. Fattal, F. Subra, H. Pinto-Alphandary, C. Malvy, C. Auclair, and P. Couvreur, 2000a. EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma related tumor in mice. Biochemical and Biophysical Research Communications 279: 401-406.
88. Lemarchand, C., R. Gref, and P. Couvreur, 2004. Polysaccharide-decorated nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 58(2): 327-341.
89. Lenaerts, V., P. Couvreur, D. Christiaens-Leyh, E. Joiris, M. Roland, B. Rollman, and P. Speiser, 1984. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 5(2): 65-68.
90. Leonard, F., R. K. Kulkarni, G. Brandes, J. Nelson, and J. J. Cameron, 1966. Synthesis and degradation of poly (alkyl α-cyanoacrylates). Journal of Applied Polymer Science 10(2): 259-272.
91. Lherm, C., R. H. Muller, F. Puisieux, and P. Couvreur, 1992. Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. International Journal of Pharmaceutics 84: 13-22.
92. Li, Y.-P., Y.-Y. Pei, Z.-H. Zhou, X.-Y. Zhang, Z.-H. Gu, J. Ding, J.-J. Zhou, and X.-J. Gao, 2001a. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-[alpha] carriers. Journal of Controlled Release 71(3): 287-296.
93. Li, Y.-P., Y.-Y. Pei, Z.-H. Zhou, X.-Y. Zhang, Z.-H. Gu, J. Ding, J.-J. Zhou, X.-J. Gao, and J.-H. Zhu, 2001b. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: Pharmacokinetics and anti-tumor effects. Biological and Pharmaceutical Bulletin 24(6): 662-665.
94. Liang, M., N. M. Davies, and I. Toth, 2008. Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared from water-in-oil microemulsions by copolymerization. International Journal of Pharmaceutics 362(1-2): 141-146.
95. Lowe, P. J. and C. S. Temple, 1994. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules-Protection against proteases and effect on intestinal absorption in rats. Journal of Pharmacy and Pharmacology 46(7): 547-552.
96. Ludwig, A., 2005. The use of mucoadhesive polymers in ocular drug delivery. Advanced Drug Delivery Reviews 57(11): 1595-1639.
97. Maincent, P., R. Le Verge, P. Sado, P. Couvreur, and J. P. Devissaguet, 1986. Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. Journal of Pharmaceutical Sciences 75(10): 955-958.
98. Marchal-Heussler, L., H. Fessi, J. P. Devissaguet, M. Hoffman, and P. Maincent, 1992. Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: Polyisobutylcyanoacrylate, polylactic-co-glycolic acid, poly-epsilon-caprolactone. S.T.P. Pharma Sciences 2(1): 98-104.
99. Mayer, C., D. Hoffmann, and M. Wohlgemuth, 2002. Structural analysis of nanocapsules by nuclear magnetic resonance. International Journal of Pharmaceutics 242(1-2): 37-46.
100. Mesiha, M. S., M. B. Sidhom, and B. Fasipe, 2005. Oral and subcutaneous absorption of insulin poly- (isobutylcyanoacrylate) nanoparticles. International Journal of Pharmaceutics 288(2): 289-293.
101. Michel, C., M. Aprahamian, L. Defontaine, P. Couvreur, and C. Damge, 1991. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. Journal of Pharmacy and Pharmacology 43(1): 1-5.
102. Monza da Silveira, A., G. Ponchel, F. Puisieux, and D. Duchene, 1998. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharmaceutical Research 15(7): 1051.
103. Muller, R. H., C. Lherm, J. Herbort, T. Blunk, and P. Couvreur, 1992. Alkylcyanoacrylate drug carriers: I. Physicochemical characterisation of nanoparticles with different alkyl chain length. International Journal of Pharmaceutics 84(1): 1-11.
104. O'Hagan, D. T., K. J. Palin, and S. S. Davis, 1989. Poly (butyl-2-cyanoacrylate) particles as adjuvants for oral immunisation. Vaccine 7: 213-216.
105. Olivier, J.-C., C. Vauthier, M. Taverna, D. Ferrier, and P. Couvreur, 1995. Preparation and characterization of biodegradable poly(isobutylcyano acrylate) nanoparticles with the surface modified by adsorption of proteins. Colloids Surfaces B: Biointerfaces 4: 349-356.
106. Oowaki, H., S. Matsuda, and N. Sakai, 2000. Non-adhesive cyanoacrylate as an embolic material for endovascular neurosurgery. Biomaterials 21: 1039-1046.
107. Peracchia, M. T., E. Fattal, D. Desmaele, M. Besnard, J. P. Noel, J. M. Gomis, M. Appel, J. d'Angelo, and P. Couvreur, 1999. Stealth(R) PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. Journal of Controlled Release 60(1): 121-128.
108. Pitaksuteepong, T., N. M. Davies, M. Baird, and T. Rades, 2004. Uptake of antigen encapsulated in poly (ethylcyanoacrylate) nanoparticles by D1-dendritic cells. Pharmazie 59(2): 134-142.
109. Pitaksuteepong, T., N. M. Davies, I. G. Tucker, and T. Rades, 2002. Factors influencing the entrapment of hydrophilic compounds in nanocapsules prepared by interfacial polymerisation of water-in-oil microemulsions. European Journal of Pharmaceutics and Biopharmaceutics 53(3): 335-342.
110. Ponchel, G. and J.-M. Irache, 1998. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Advanced Drug Delivery Reviews 34(2-3): 191-219.
111. Puglisi, G., M. Fresta, G. Giammona, and C. A. Ventura, 1995. Influence of the preparation conditions on poly- (ethylcyanoacrylate) nanocapsule formation. International Journal of Pharmaceutics 125(2): 283-287.
112. Quinn, J., J. Maw, K. Ramotar, G. Wenckebach, and G. Wells, 1997. Octylcyanoacrylate tissue adhesive versus suture wound repair in a contaminated wound model. Surgery 122(1): 69-72.
113. Radwan, M. A., 2001. Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous administration in diabetic rats. Drug Development and Industrial Pharmacy 27(9): 981-989.
114. Radwan, M. A. and H. Y. Aboul-Enein. 2002. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. Journal of Microencapsulation 19(2): 225-235.
115. Reddy, L. H. and R. R. Murthy, 2004. Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharmaceutica 54(2): 103-118.
116. Ritschel, W. A., 1991. Microemulsions for improved peptide absorption from the gastrointestinal-tract. Methods and Findings in Experimental and Clinical Pharmacology 13(3): 205-220.
117. Rollot, M., P. Couvreur, L. Roblot-Treupel, and F. Puisieux, 1986. Physicochemical and morphological characterization of polyisobutyl cyanoacrylate nanocapsules. Journal of Pharmaceutical Sciences 75(4): 361-364.
118. Roques, M., C. Damge, C. Michel, C. Staedel, G. Cremel, and P. Hubert, 1992. Encapsulation of insulin for oral administration preserves interaction of the hormone with its receptor in vitro. Diabetes 41(4): 451-456.
119. Sai, P., Ch. Damge, A. S. Rivereau, A. Hoeltzel, and E. Gouin, 1996. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. Journal of Autoimmunity 9(6): 713-721.
120. Schneider, T., A. Becker, K. Ringe, A. Reinhold, R. Firsching, and B. A. Sabel, 2008. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. Journal of Neuroimmunology 195(1-2): 21-27.
121. Schroeder, U., H. Schroeder, and B. A. Sabel, 2000. Body distribution of 3HH-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after I.V. injections to mice. Life Sciences 66(6): 495-502.
122. Simeonova, M., M. Antcheva, and K. Chorbadjiev, 2003. Study on the effect of polybutyl-2-cyanoacrylate nanoparticles and their metabolites on the phagocytic activity of peritoneal exudate cells of mice. Biomaterials 24(2): 313-320.
123. Stella, B., S. Arpicco, M. T. Peracchia, D. Desmaele, J. Hoebeke, M. Renoir, J. D'Angelo, L. Cattel, and P. Couvreur, 2000. Design of folic acid-conjugated nanoparticles for drug targeting. Journal of Pharmaceutical Sciences 89(11): 1452-1464.
124. Stieneker, F., G. Kersten, L. van Bloois, D. J. A. Crommelin, S. L. Hem, J. Lower, and J. Kreuter. 1995. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 13(1): 45-53.
125. Toriumi, D. M., W. F. Raslan, M. Friedmann, and M. E. Tardy, 1991. Variable histotoxicity of histoacryl when used in a subcutaneous site: An experimental study. Laryngoscope 101: 339-343.
126. Vauthier, C., C. Dubernet, C. Chauvierre, I. Brigger, and P. Couvreur, 2003a. Drug delivery to resistant tumors:The potential of poly(alkyl cyanoacrylate) nanoparticles. Journal of Controlled Release 93(2): 151-160.
127. Vauthier, C., C. Dubernet, E. Fattal, H. Pinto-Alphandary, and P. Couvreur, 2003b. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Advanced Drug Delivery Reviews 55(4): 519-548.
128. Vauthier, C., D. Labarre, and G. Ponchel, 2007. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. Journal of Drug Targeting 15(10): 641-663.
129. Vranckx, H., M. Demoustier, and M. Deleers, 1996. A new nanocapsule formulation with hydrophilic core:Application to the oral administration of salmon calcitonin in rats. European Journal of Pharmaceutics and Biopharmaceutics 42(5): 345-347.
130. Watnasirichaikul, S., N. M. Davies, T. Rades, and I. G. Tucker, 2000. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharmaceutical Research 17(6): 684-689.
131. Watnasirichaikul, S., T. Rades, I. G. Tucker, and N. M. Davies, 2002a. Effects of formulation variables on characteristics of poly(ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. International Journal of Pharmaceutics 235(1-2): 237-246.
132. Watnasirichaikul, S., T. Rades, I. G. Tucker, and N. M. Davies, 2002b. In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. Journal of Pharmacy and Pharmacology 54(4): 473-480.
133. Weiss, C. K., U. Ziener, and K. Landfester, 2007. A route to nonfunctionalized and functionalized poly(nbutylcyanoacrylate) nanoparticles: Preparation in miniemulsion. Macromolecules 40(4): 928-938.
134. WHO/UNICEF (Ed.), 1996. State of the World's Vaccines and Immunization. Geneva: WHO/UNICEF.
135. Wilson, B., M. K. Samanta, K. Santhi, K. P. S. Kumar, N. Paramakrishnan, and B. Suresh, 2008. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 70(1): 75-84.
136. Wohlgemuth, M. and C. Mayer, 2003. Pulsed field gradient NMR on polybutylcyanoacrylate nanocapsules. Journal of Colloid and Interface Science 260(2): 324-331.
137. Wolberg, H. and A. Lippoldt, 2002. Tight junctions of the blood-brain-barrier: Development, composition and regulation. Vascular Pharmacology 38: 323-337.
138. Yang, S. C., H. X. Ge, Y. Hu, X. Q. Jiang, and C. Z. Yang, 2000. Doxorubicin-loaded poly(butylcyanoacrylate) nanoparticles produced by emulsifier-free emulsion polymerization. Journal of Applied Polymer Science 78(3): 517-526.
139. Zhang, Q., Z. Shen, and T. Nagai. 2001. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. International Journal of Pharmaceutics 218(1-2) :75-80.
140. Zimmer, A., 1999. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. A Companion to Methods in Enzymology 18: 286-295.